Your DNA may hold crucial information that your physician overlooks when prescribing medications.
A study released on Wednesday in Science Translational Medicine revealed that nearly 25% of participants received a prescription that could have been altered in terms of the drug or dosage due to their genetic makeup.
The research, conducted by scientists at the University of Pittsburgh, analyzed 16 genes that influence the body’s reaction to various medications.
DNA samples from 98,590 individuals enrolled in the National Institutes of Health’s All of Us Research Program were scrutinized and matched with their medical histories when accessible.
Each participant possessed at least one significant genetic variation that could modify their response to specific medications, with an average of nine variations per person. Of those with both genetic and clinical data, 24.4% had been prescribed at least one medication that should have been substituted with a different drug or had an adjusted dosage according to genetic guidelines.
Nonetheless, the study did not establish whether patients faced side effects or if their medications’ effectiveness was compromised due to their genetic profiles.
Dr. Philip Empey, the study’s senior author and an associate professor at the University of Pittsburgh’s pharmacy school, emphasized that understanding a patient’s genetic information could minimize the trial-and-error approach often seen in medicine.
“Any effort to accurately predict from the outset what medications and dosages are optimal will significantly lessen that trial and error,” he stated.

A pharmacist organizes prescriptions at a Vancouver pharmacy in October 2022. Genetic differences can influence how individuals react to specific medications, which may necessitate dose adjustments or alternative prescriptions by doctors. (Darryl Dyck/The Canadian Press)
Identifying the appropriate medication
Omeprazole and pantoprazole for acid reflux, along with atorvastatin for cholesterol management, were among the frequently prescribed medications to participants whose genetic profiles indicated a need for treatment modifications.
Empey noted that certain genetic variations might elevate the risk of muscle issues for patients taking statins like atorvastatin, which are intended to lower the likelihood of heart attacks or strokes.
This insight could assist healthcare providers in selecting alternative drugs or modifying treatment plans.
“It empowers clinicians to make improved decisions, such as, ‘Perhaps this cholesterol medication isn’t suitable. We might start with a lower dose, set a maximum limit, or monitor for specific toxicities more closely,'” Empey explained.
In some cases, the implications can be even more severe.
Experts consulted by CBC News noted that genetic testing can pinpoint patients who may not respond effectively to clopidogrel (Plavix), a medication prescribed to avert blood clots following cardiac stenting, enabling physicians to switch to an alternative treatment.

Dr. James Kennedy leads the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health. He states that while genetic testing can aid in medication selection, it is essential to consider other factors such as diet, lifestyle, and existing medications. (CBC)
A guideline, not a certainty
Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at Toronto’s Centre for Addiction and Mental Health (CAMH), indicated that the study’s findings were not unexpected, but he was notably impressed by the genetic diversity and inclusion of individuals of African descent.
Kennedy’s team has conducted genetic testing for around 11,000 patients, many of whom had already tried two or three antidepressants without finding satisfactory outcomes.
Approximately 8% to 10% of individuals metabolize certain commonly prescribed antidepressants at an unusually slow rate, leading to medication buildup and potentially resulting in side effects, he noted.
Kennedy added that genetic testing is particularly beneficial for patients who have previously struggled with multiple medications.
However, he cautioned that genetic testing alone cannot predict a patient’s reaction to a specific drug. Other factors, including the patient’s current medications, smoking habits, and diet, must also be taken into account.
“We explain, ‘Here’s your genetic blueprint, these are some tendencies you may have, and now let’s discuss all the additional factors to consider before making a final decision,'” he remarked.
A 2023 European clinical trial referenced in the study found that conducting genetic testing prior to prescribing certain medications decreased adverse drug reactions. However, the integration of such testing into routine practice in Canada poses challenges.

A researcher at the University of Calgary displays a diagnostic kit utilized for identifying genetic variations in February 2024. Although such testing could assist physicians in customizing medications for individual patients, practical issues and costs have hindered its widespread implementation in Canada. (Jeff McIntosh/The Canadian Press)
Barriers to widespread genetic testing in Canada
Dr. Jacob Udell, a cardiologist in Toronto, expressed admiration for the study, especially noting the genetic diversity of its participants, yet highlighted that few healthcare providers in Canada or the U.S. routinely test patients for genetic variations that influence medication metabolism.
“This is certainly not a common practice among frontline clinicians,” he remarked.
Udell mentioned that for many conditions, physicians can prescribe a medication, observe the patient’s response, and make necessary adjustments, usually without serious repercussions. This method can be more feasible than consistently screening for genetic variations.
He also questioned the necessity of prioritizing widespread testing when Canada’s healthcare system is struggling to provide fundamental services.
“Our primary goal is to ensure everyone has access to a family doctor,” he stated.
In addition to testing costs, Udell pointed out that healthcare providers would require access to genetic test results and the expertise to interpret them.
Empey concurred that making genetic testing standard practice would necessitate considerable investments in training, infrastructure, and new systems for sharing results among healthcare professionals.
“The scientific basis is strong for many medications. The challenge of implementation is more economic, procedural, and educational,” he commented.
For the time being, Empey suggested that patients inquire with their doctors or pharmacists about the potential benefits of genetic testing and share any relevant results.
Udell cautioned that private genetic testing may become increasingly accessible for those who can afford it, “but this does not assist those who cannot afford such testing.”
